Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) reported recently that a manuscript entitled ?Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine as Second- or Third-Line Therapy in Patients with Metastatic Colorectal Cancer? reporting Phase 2 activity of KRX-0401 (perifosine) in the treatment of patients with refractory, advanced colorectal cancer (mCRC), was selected for publication in the October 3, 2011 online edition of the Journal of Clinical Oncology.? Efficacy data from this study was presented in June 2010 at the 46th Annual Meeting of the American Society of Clinical Oncology.
According to the press release on Keryx?s website,
?Based on the data, in which the combination of P-CAP demonstrated statistical significance with respect to median overall survival and median time to tumor progression, the investigators concluded that the P-CAP combination showed promising clinical activity compared to single-agent capecitabine, and that the difference in clinical outcome seen with the addition of perifosine was impressive.?
Keryx is currently investigating perifosine as a novel, potentially first-in-class, oral anti-cancer drug candidate that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway under a Special Protocol Assessment and with Fast Track designation from the Food and Drug Administration in a Phase 3 trial.? Enrollment was completed in July of 2011 for the trial entitled ?X-PECT? (Xeloda? + Perifosine Evaluation in Colorectal cancer Treatment) with completion expected in the first quarter of 2012.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. (NASDAQ:AEZS) in the United States, Canada and Mexico.
Keryx Biopharmaceuticals (KERX) Stock Quote and News:
Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (?us? or ?we?) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/?page_id=190.
Posted in Biotechnology News, Blog, More Stock Market News | No Comments ?
Source: http://www.otcshowcase.com/?p=3448
building 7 parenthood dadt dadt orcl william shatner brooke mueller
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.